CEACAM5 and non-small cell lung carcinoma: In a multicenter investigation encompassing 189 subjects with advanced NSCLC subjected to Nivolumab as a second- or later-line treatment, Kataoka et al. uncovered an association linking pre-immunotherapy CEA concentrations to PFS; a crucial threshold of 13.8 ng/ml for CEA was established (75).